Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Shah, Bijal; Smith, Nathaniel J.; Feng, Chaoling; Jeyakumar, Sushanth; Castaigne, Jean‐Gabriel; Faghmous, Imi; Masouleh, Behzad Kharabi; Malone, Daniel C.; Bishop, Michael

doi:10.1007/s12325-022-02201-6

Cited by 6 publications

(2 citation statements)

References 31 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have been limited to cost-effectiveness analyses based on listed drug prices or have used algorithms or proxies as estimates for cost. [17][18][19][20][21] There are also multiple studies investigating the cost of CAR-T therapy delivery in other countries' health systems, [22][23][24][25][26][27][28][29] however studies of comprehensive real-life cost of cellular therapy for pediatric B-ALL are not available in the US.…”

Section: Introductionmentioning

confidence: 99%

Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Hoover,

Reimche,

Watson

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and financial toxicity experienced by patients and society requires evaluation. This study aims to assess the total cost of CAR-T therapy for pediatric ALL patients with commercial insurance coverage in the United States. STUDY DESIGN: Using de-identified commercial insurance data from the OptumLabs Data Warehouse, a cohort of 37 patients, aged 1-25 years, with B-ALL treated with CAR-T therapy between Oct 2016 and Dec 2021 in the United States was identified. Cost was evaluated for a 90 day period encompassing CAR-T infusion and by administration and complication characteristics. RESULTS: Among the 37 identified ALL patients that received a CAR-T product infusion, 14 patients were female, median age at administration was 13 years. The median 90-day total cost was $620,500 (Mean: $589,108). Inpatient cost accounted for approximately 71% of the total cost with an average of 28 inpatient days per patient. Although inpatient cost was slightly higher in the older age group (aged 10-25 years) and in patients with a code for CRS, these differences were not statistically significant. CONCLUSION: This real-world cost analysis shows for the first time the encompassing cost of CAR-T therapy for pediatric ALL patients in the US with commercial insurance. This study provides a valuable benchmark that can be used to analyze the financial implications of CAR-T therapy for pediatric ALL therapy on health systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Hoover,

Reimche,

Watson

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis

Hoover,

Reimche,

Watson

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundB‐lineage acute lymphoblastic leukemia (B‐ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial burden experienced by patients and society requires evaluation.AimsThis study aims to assess the utilization and cost of care for chimeric antigen receptor T‐cell (CAR‐T) therapy for pediatric ALL patients with commercial insurance coverage in the United States.Methods and ResultsUsing de‐identified commercial insurance data from the OptumLabs® Data Warehouse, a cohort of 37 patients, aged 1‐25 years, with B‐ALL treated with CAR‐T therapy between Oct 2016 and Dec 2021 in the United States was identified. Cost was evaluated for a 90 day period encompassing CAR‐T infusion and by administration and complication characteristics. Among the 37 identified B‐ALL patients that received a CAR‐T product infusion, 14 patients were female, median age at administration was 13 years. The median 90‐day total cost was $620,500 (Mean: $589,108). Inpatient cost accounted for approximately 71% of the total cost with an average of 28 inpatient days per patient. Although inpatient cost was slightly higher in the older age group (aged 10‐25 years) and in patients with a code for cytokine release syndrome (CRS), these differences were not statistically significant.ConclusionThis real‐world cost analysis shows for the first time the encompassing cost of CAR‐T therapy for pediatric B‐ALL patients in the US with commercial insurance. This study provides a valuable benchmark that can be used to analyze the financial implications of CAR‐T therapy for pediatric B‐ALL therapy on health systems.

show abstract

Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia

et al. 2023

View full text Add to dashboard Cite

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Cited by 6 publications

References 31 publications

Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis

Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia

Contact Info

Product

Resources

About